The only candidate biomarkers, for which published literature indicates a high predictive clinical performance is MGMT testing in glioblastomas of the elderly and 1p19q status in anaplastic oligodendroglial tumors [14, 20, 51, 52]. The gene discussed is MGMT; the disease is glioblastoma.